Panelists discuss the findings from the ALINA study on adjuvant alectinib vs chemotherapy in resected ALK-positive NSCLC, considering how these results may influence early-stage management, sequencing strategies for ALK inhibitors, and the role of resistance mechanisms in treatment decisions.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Dr Rotow: The ALINA study included exploratory biomarker analyses in patients with resected ALK-positive NSCLC treated with adjuvant alectinib vs chemotherapy. (Solomon BJ, et al. 2024. ESMO. 1206MO)
What are your thoughts on these findings, and how might they impact your approach to early-stage ALK-positive NSCLC management?
What strategies are you currently using for sequencing ALK inhibitors?
How do resistance mechanisms influence your sequence decisions?
What data support using lorlatinib in the first-line setting vs reserving it for later lines?